{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:40Z","timestamp":1788952120910,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) main pathological feature involves degeneration of dopamine (DA) neurons in the brain substantia nigra (SN). Female gonadal steroids are shown to be neuroprotective in animal models of PD and tested mainly in male and less in female animals. Since most women with PD are in menopause the present study tested ovariectomized (OVX) female mice as a model of the hormonal condition of menopause. This study sought the neuroprotective effect of the selective estrogen receptor modulator (SERM) raloxifene and progesterone alone and in combination to protect DA neurons in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned mice as a model of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were treated with vehicle, raloxifene (2.5\u202fmg\/kg, b.i.d., subcutaneous), progesterone (1 \u03bcg, b.i.d., subcutaneous) and their combination for 10\u202fdays and administered MPTP (5.5\u202fmg\/kg, intraperitoneal) or saline on the 5th day; brains and uteri were collected thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Raloxifene treatment led to only small increases in uterine weights less than an average of intact mice uterine weights and no effect of progesterone. OVX MPTP-lesioned female mice showed a loss of striatal DA and metabolites content similarly prevented by treatments with raloxifene, progesterone and their combination. By contrast, striatal serotonin and metabolite remained unchanged. Striatal glial fibrillary acidic protein (GFAP), an astrogliosis marker, levels were elevated in MPTP-lesioned mice and this was similarly prevented with the hormonal treatment alone or in combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Raloxifene and progesterone treatment was neuroprotective without excessive uterine stimulation in OVX mice supporting repurposing of these drugs for PD and their high translational value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2026.1870069","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:42Z","timestamp":1788948702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Raloxifene and progesterone neuroprotection in a female mouse model of Parkinson\u2019s disease"],"prefix":"10.3389","volume":"20","author":[{"given":"Morgane M.","family":"Andr\u00e9","sequence":"first","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bourque","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Rieux","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Soulet","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Centre de Recherche du CHU de Qu\u00e9bec, Axe Neurosciences","place":["Qu\u00e9bec, QC, Canada"]},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval","place":["Qu\u00e9bec, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2019.10.019","article-title":"Sex differences in Parkinson's disease presentation and progression","volume":"69","author":"Abraham","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","article-title":"Selective Estrogen Receptor Modulators","volume":"10","author":"An","year":"2016","journal-title":"Asian Spine J."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","article-title":"Medical management and prevention of motor complications in Parkinson's disease","volume":"17","author":"Aradi","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.yfrne.2018.09.001","article-title":"Molecular mechanisms involved in the protective actions of selective estrogen receptor modulators in brain cells","volume":"52","author":"Baez-Jurado","year":"2019","journal-title":"Front. Neuroendocrinol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.lfs.2011.03.010","article-title":"The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease","volume":"88","author":"Baraka","year":"2011","journal-title":"Life Sci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510x(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.yfrne.2009.04.014","article-title":"Neuroprotective actions of sex steroids in Parkinson's disease","volume":"30","author":"Bourque","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000438789","article-title":"Neuroprotective effect of progesterone in MPTP-treated male mice","volume":"103","author":"Bourque","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.neurobiolaging.2014.03.017","article-title":"Raloxifene activates G protein-coupled estrogen receptor 1\/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice","volume":"35","author":"Bourque","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neuropharm.2018.04.005","article-title":"Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease","volume":"147","author":"Bourque","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"105479","DOI":"10.1016\/j.neubiorev.2023.105479","article-title":"Neuroactive steroids and Parkinson's disease: review of human and animal studies","volume":"156","author":"Bourque","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5","article-title":"Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice","volume":"37","author":"Callier","year":"2000","journal-title":"Synapse"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/syn.1067","article-title":"Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl\/6 mice","volume":"41","author":"Callier","year":"2001","journal-title":"Synapse"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1365-2826.2010.02064.x","article-title":"Effect of short-and long-term gonadectomy on neuroactive steroid levels in the central and peripheral nervous system of male and female rats","volume":"22","author":"Caruso","year":"2010","journal-title":"J. Neuroendocrinol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson's disease in women and men: what's the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2015.05.017","article-title":"GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease","volume":"82","author":"Cote","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-017-0043-3","article-title":"The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis","volume":"4","author":"de Boer","year":"2018","journal-title":"NPJ Schizophr."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp. Neurol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.brainres.2013.07.014","article-title":"Progesterone's role in neuroprotection, a review of the evidence","volume":"1530","author":"Deutsch","year":"2013","journal-title":"Brain Res."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/14740338.2015.1014799","article-title":"Selective estrogen receptor modulators in clinical practice: a safety overview","volume":"14","author":"Ellis","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson's disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040861","article-title":"Estradiol and estrogen-like alternative therapies in use: the importance of the selective and non-classical actions","volume":"861","author":"Farkas","year":"2022","journal-title":"Biomedicine"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070945","article-title":"Neurosteroids progesterone and Dehydroepiandrosterone: molecular mechanisms of action in neuroprotection and Neuroinflammation","volume":"945","author":"Fedotcheva","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","volume-title":"Anesthesia and Analgesia in Laboratory Animals","author":"Fish","year":"2008"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1210\/endrev\/bnab011","article-title":"Hormone therapy in menopause: concepts, controversies, and approach to treatment","volume":"42","author":"Flores","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fneur.2017.00397","article-title":"Increase of reproductive life span delays age of onset of Parkinson's disease","volume":"8","author":"Frentzel","year":"2017","journal-title":"Front. Neurol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/OGX.0b013e31828baef9","article-title":"Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications","volume":"68","author":"Gizzo","year":"2013","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00001756-200002070-00024","article-title":"Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice","volume":"11","author":"Grandbois","year":"2000","journal-title":"Neuroreport"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"108784","DOI":"10.1016\/j.neuropharm.2021.108784","article-title":"Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice","volume":"201","author":"Isenbrandt","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e12782","DOI":"10.1111\/jne.12782","article-title":"Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease","volume":"32","author":"Jarras","year":"2020","journal-title":"J. Neuroendocrinol."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/genes13030471","article-title":"Monogenic Parkinson's disease: genotype, phenotype, pathophysiology, and genetic testing","volume":"471","author":"Jia","year":"2022","journal-title":"Genes (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.maturitas.2016.01.015","article-title":"Modeling menopause: the utility of rodents in translational behavioral endocrinology research","volume":"87","author":"Koebele","year":"2016","journal-title":"Maturitas"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5812\/ijem.6615","article-title":"The role of estrogen in the treatment of men with schizophrenia","volume":"11","author":"Kulkarni","year":"2013","journal-title":"Int. J. Endocrino.l Metab."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jcma.2013.03.010","article-title":"The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis","volume":"76","author":"Lee","year":"2013","journal-title":"J. Chin. Med. Assoc."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neuropharm.2015.05.015","article-title":"The 5alpha-reductase inhibitor Dutasteride but not finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease","volume":"97","author":"Litim","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jsbmb.2017.09.021","article-title":"Effect of the 5alpha-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice","volume":"174","author":"Litim","year":"","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neubiorev.2015.09.024","article-title":"Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson's disease","volume":"67","author":"Litim","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuropharm.2017.02.007","article-title":"Effects of progesterone administered after MPTP on dopaminergic neurons of male mice","volume":"117","author":"Litim","year":"","journal-title":"Neuropharmacology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1671552","DOI":"10.3389\/fnagi.2025.1671552","article-title":"The estrogen-brain interface in neuroinflammation: a multidimensional mechanistic insight","volume":"17","author":"Lu","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2008.04.008","article-title":"Estrogen and SERM neuroprotection in animal models of Parkinson's disease","volume":"290","author":"Morissette","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mds.27216","article-title":"Levodopa: a new look at an old friend","volume":"33","author":"Olanow","year":"2018","journal-title":"Mov. Disord."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front. Public Health"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1093\/brain\/awac440","article-title":"Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study","volume":"146","author":"Pesce","year":"2022","journal-title":"Brain"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.brainresbull.2022.06.019","article-title":"Differential contribution of estrogen receptors to the intestinal therapeutic effects of 17beta-estradiol in a murine model of Parkinson's disease","volume":"187","author":"Poirier","year":"2022","journal-title":"Brain Res. Bull."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2016.08.004","article-title":"Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease","volume":"48","author":"Poirier","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF01249445","article-title":"Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis","volume":"38","author":"Riederer","year":"1976","journal-title":"J. Neural Transm."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1212\/01.wnl.0000280573.30975.6a","article-title":"Increased risk of parkinsonism in women who underwent oophorectomy before menopause","volume":"70","author":"Rocca","year":"2008","journal-title":"Neurology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e2238663","DOI":"10.1001\/jamanetworkopen.2022.38663","article-title":"Association of Premenopausal Bilateral Oophorectomy with Parkinsonism and Parkinson Disease","volume":"5","author":"Rocca","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","article-title":"Progesterone and breast Cancer","volume":"41","author":"Trabert","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207586","article-title":"Raloxifene as treatment for various types of brain injuries and neurodegenerative diseases: a good start","volume":"7586","author":"Veenman","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00737-017-0773-2","article-title":"Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials","volume":"21","author":"Wang","year":"2018","journal-title":"Arch. Womens Ment. Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neuroscience.2015.05.068","article-title":"Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice","volume":"301","author":"Willard","year":"2015","journal-title":"Neuroscience"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"391-402, 402 e391-392","DOI":"10.1016\/j.annemergmed.2006.07.932","article-title":"ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury","volume":"49","author":"Wright","year":"2007","journal-title":"Ann. Emerg. Med."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/cc6887","article-title":"Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial","volume":"12","author":"Xiao","year":"2008","journal-title":"Crit. Care"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3000605261417447","DOI":"10.1177\/03000605261417447","article-title":"Safety profile of progesterone: insights from an FDA adverse event reporting system (FAERS)-based pharmacovigilance study","volume":"54","author":"Xu","year":"2026","journal-title":"J. Int. Med. Res."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41531-024-00855-3","article-title":"Systemically circulating 17beta-estradiol enhances the neuroprotective effect of the smoking cessation drug cytisine in female parkinsonian mice","volume":"11","author":"Zarate","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.schres.2018.01.017","article-title":"Adjunctive raloxifene for postmenopausal women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"197","author":"Zhu","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s44220-023-00125-w","article-title":"Ultra-high-field 7T MRI reveals changes in human medial temporal lobe volume in female adults during menstrual cycle","volume":"1","author":"Zsido","year":"2023","journal-title":"Nat. Ment. Health"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1870069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:44Z","timestamp":1788948704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1870069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":61,"alternative-id":["10.3389\/fnins.2026.1870069"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1870069","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1870069"}}